drug
bivalirudin
Marketedupdated 4mo agoby Avenacy Inc
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jul 27, 2028
~1.9 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (8)
- May 20, 2039method-of-use (U-3817)US 11903993
- May 20, 2039method-of-use (U-3817)US 11918622
- May 20, 2039formulationUS 11992514
- May 20, 2039formulationUS 12472224
- Jan 27, 2029patentUS 7582727*PED2.4y
- Jan 27, 2029patentUS 7598343*PED2.4y
- Jul 27, 2028formulationUS 75827271.9y
- Jul 27, 2028formulationUS 75983431.9y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 7h ago
Found something off?
comments(0)
5-min edit window · permanent after that